Synagis and Urinary tract infection - a phase IV clinical study of FDA data

Summary:

Urinary tract infection is reported as a side effect among people who take Synagis (palivizumab), especially for people who are male, 0-1 old, have been taking the drug for 1 - 6 months also take Amoxicillin, and have Premature baby.

The phase IV clinical study analyzes which people have Urinary tract infection when taking Synagis. It is created by eHealthMe based on reports of 19,108 people who have side effects when taking Synagis from the FDA, and is updated regularly.

What is Synagis?

Synagis has active ingredients of palivizumab. eHealthMe is studying from 19,114 Synagis users. Check the latest studies of Synagis.

What is Urinary tract infection?

Urinary tract infection is found to be associated with 3,014 drugs and 3,957 conditions by eHealthMe. Check the latest studies of Urinary tract infection.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 29, 2026

19,108 people reported to have side effects when taking Synagis.
Among them, 167 people (0.87%) have Urinary tract infection.

Could Synagis cause Urinary tract infection?

Among these 167 people:

How long have people been on Synagis when they have Urinary tract infection? *

Click here to view more results

What is the gender of people who have Urinary tract infection when taking Synagis? *

Click here to view

What is the age of people who have Urinary tract infection when taking Synagis? *

Click here to view more results

* Approximation only. Some reports may have incomplete information.

Do you take Synagis and have Urinary tract infection?

- Check whether Urinary tract infection is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Synagis:

Synagis (19,114 reports)

Urinary tract infection treatments and more:

Urinary tract infection (281,659 reports)

How severe was Urinary tract infection and when was it recovered:

Urinary tract infection in Synagis

Expand to all the drugs that have ingredients of palivizumab:

Urinary tract infection and drugs with ingredients of palivizumab (156 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Synagis:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Urinary tract infection:

Urinary tract infection (3,014 drugs)

Browse all the conditions that are associated with Urinary tract infection:

Urinary tract infection (3,957 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on palivizumab (the active ingredients of Synagis) and Synagis (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.